Currently, there are 3.10B common shares owned by the public and among those 3.10B shares have been available to trade.
The company’s stock has a 5-day price change of -2.11% and -3.61% over the past three months. AZN shares are trading 14.14% year to date (YTD), with the 12-month market performance up to 13.33% higher. It has a 12-month low price of $60.47 and touched a high of $87.68 over the same period. AZN has an average intraday trading volume of 4.38 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.48%, -5.79%, and 4.80% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Astrazeneca plc ADR (NASDAQ: AZN) shares accounts for 16.27% of the company’s 3.10B shares outstanding.
It has a market capitalization of $238.34B and a beta (3y monthly) value of 0.48. The stock’s trailing 12-month PE ratio is 37.25, while the earnings-per-share (ttm) stands at $2.06. The company has a PEG of 2.84 and a Quick Ratio of 0.69 with the debt-to-equity ratio at 0.85. Price movements for the stock have been influenced by the stock’s volatility, which stands at 0.87% over the week and 1.34% over the month.
Analysts forecast that Astrazeneca plc ADR (AZN) will achieve an EPS of 1.04 for the current quarter, 0.98 for the next quarter and 5.67 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.99 while analysts give the company a high EPS estimate of 0.99. Comparatively, EPS for the current quarter was 0.87 a year ago. Earnings per share for the fiscal year are expected to increase by 12.87%, and 15.56% over the next financial year. EPS should shrink at an annualized rate of 13.10% over the next five years, compared to 17.72% over the past 5-year period.
Goldman coverage for the Astrazeneca plc ADR (AZN) stock in a research note released on May 30, 2024 offered a Buy rating with a price target of $97. Morgan Stanley on their part issued Overweight rating on January 23, 2024.
